| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 21.34% | Goldman Sachs | $19 → $17 | Maintains | Buy |
| 08/07/2023 | 78.44% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 06/13/2023 | 35.62% | Goldman Sachs | $20 → $19 | Maintains | Buy |
| 05/15/2023 | 39.19% | UBS | $18.5 → $19.5 | Maintains | Neutral |
| 05/08/2023 | 92.72% | Wells Fargo | $29 → $27 | Maintains | Overweight |
| 05/08/2023 | 64.17% | TD Cowen | $21 → $23 | Maintains | Outperform |
| 01/25/2023 | 78.44% | HC Wainwright & Co. | $28 → $25 | Maintains | Buy |
| 12/14/2022 | 12.06% | UBS | → $15.7 | Initiates Coverage On | → Neutral |
| 08/18/2022 | 64.17% | Goldman Sachs | $14 → $23 | Upgrades | Neutral → Buy |
| 06/28/2022 | 42.76% | Cowen & Co. | $18 → $20 | Maintains | Outperform |
| 05/09/2022 | 42.76% | Cowen & Co. | $18 → $20 | Maintains | Outperform |
| 04/21/2022 | 107% | Wells Fargo | $27 → $29 | Maintains | Overweight |
| 02/28/2022 | 99.86% | HC Wainwright & Co. | $19 → $28 | Maintains | Buy |
| 11/23/2021 | 114.13% | Wolfe Research | → $30 | Upgrades | Peer Perform → Outperform |
| 11/23/2021 | 64.17% | Cowen & Co. | $12 → $23 | Upgrades | Market Perform → Outperform |
| 10/15/2021 | -21.48% | Goldman Sachs | $6 → $11 | Maintains | Neutral |
| 10/08/2021 | -21.48% | Wells Fargo | $8 → $11 | Maintains | Overweight |
| 10/04/2021 | 35.62% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 03/24/2021 | -42.9% | Wells Fargo | → $8 | Upgrades | Equal-Weight → Overweight |
| 12/15/2020 | -71.45% | Wells Fargo | → $4 | Downgrades | Overweight → Equal-Weight |
| 03/27/2020 | -92.86% | Goldman Sachs | $2 → $1 | Maintains | Neutral |
| 02/11/2020 | — | Raymond James | Upgrades | Underperform → Market Perform |
What is the target price for Calumet Specialty Prods (CLMT)?
The latest price target for Calumet Specialty Prods (NASDAQ: CLMT) was reported by Goldman Sachs on October 31, 2023. The analyst firm set a price target for $17.00 expecting CLMT to rise to within 12 months (a possible 21.34% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Calumet Specialty Prods (CLMT)?
The latest analyst rating for Calumet Specialty Prods (NASDAQ: CLMT) was provided by Goldman Sachs, and Calumet Specialty Prods maintained their buy rating.
When is the next analyst rating going to be posted or updated for Calumet Specialty Prods (CLMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calumet Specialty Prods, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calumet Specialty Prods was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
Is the Analyst Rating Calumet Specialty Prods (CLMT) correct?
While ratings are subjective and will change, the latest Calumet Specialty Prods (CLMT) rating was a maintained with a price target of $19.00 to $17.00. The current price Calumet Specialty Prods (CLMT) is trading at is $14.01, which is out of the analyst's predicted range.
